Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique
Launched by UNIVERSITY OF WASHINGTON · Feb 24, 2015
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
For over 10 years, services to prevent maternal to child HIV-1 transmission (PMTCT) have been scaled-up and integrated into antenatal care (ANC) in the national health system across Mozambique. In 2004, scale-up of anti-retroviral treatment (ART) also began in Mozambique and is now provided at hundreds of health units. In 2010, the World Health Organization developed new treatment guidelines, termed "Option B" that emphasized early initiation of ART in antenatal care for all HIV-positive pregnant women. In 2012, the WHO issued a programmatic update endorsing a third option termed "Option B+...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women who test HIV-positive in antenatal care services at target health facilities
- Exclusion Criteria:
- • Pregnant women who arrived at health facilities who already have tested positive
- • HIV-positive pregnant women who cannot start ART
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beira, Sofala, Mozambique
Patients applied
Trial Officials
Rachel Chapman, PhD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials